Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous cSVF for Frailty and Aging
NCT03514537Suspended
- Sponsor
- Healeon Medical
- Start
- Mar 2018
- Primary completion
- Mar 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of autologous adipose stromal vascular fraction in frailty syndrome and aging, sponsored by Healeon Medical. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 6 months. Started Mar 2018; status: suspended.
02
Drugs
autologous adipose stromal vascular fraction
03
Conditions
frailty syndromeaging
Beyond the preview
Go deeper on NCT03514537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03514537.